Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Don't Panic! Novartis Is Still Invested In CAR-T Despite 2Q Silence

Executive Summary

Novartis AG's CAR-T cell therapy CTL019, set to be the first in this class to achieve a US FDA filing, might not be an immediate blockbuster owing to its tricky treatment logistics, small initial indication and a lack of physician and patient exposure, but it is still a game changer in immuno-oncology, says Dr. Oz Azam, Novartis's head of cell therapies.


Related Content

CAR-T Update: Kite's Filing Coming Soon
Juno ROCKETs On Fast Clinical Hold Resolution


Related Companies